Persistent mutation burden drives sustained anti-tumor immune responses

Tumor mutation burden is an imperfect proxy of tumor foreignness and has therefore failed to consistently demonstrate clinical utility in predicting responses in the context of immunotherapy. We evaluated mutations in regions of the genome that are unlikely to undergo loss in a pan-cancer analysis a...

Descripción completa

Detalles Bibliográficos
Autores principales: Niknafs, Noushin, Balan, Archana, Cherry, Christopher, Hummelink, Karlijn, Monkhorst, Kim, Shao, Xiaoshan M., Belcaid, Zineb, Marrone, Kristen A., Murray, Joseph, Smith, Kellie N., Levy, Benjamin, Feliciano, Josephine, Hann, Christine L., Lam, Vincent, Pardoll, Drew M., Karchin, Rachel, Seiwert, Tanguy Y., Brahmer, Julie R., Forde, Patrick M., Velculescu, Victor E., Anagnostou, Valsamo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941047/
https://www.ncbi.nlm.nih.gov/pubmed/36702947
http://dx.doi.org/10.1038/s41591-022-02163-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941047/
https://www.ncbi.nlm.nih.gov/pubmed/36702947
http://dx.doi.org/10.1038/s41591-022-02163-w

Ejemplares similares